STOCK TITAN

Immuron Limited Announces Participation in the LD Micro Invitational XIII

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings.

Immuron Limited is scheduled to present on June 6th at 02:00 PM PT. Steven Lydeamore, CEO, will be leading the presentation.

We invited interested parties to register for the event here: https://ldinv13.sequireevents.com/

About Immuron Limited

Immuron Limited is commercializing and developing a novel class of specifically targeted polyclonal antibodies which are delivered within the gastrointestinal tract and do not cross into the bloodstream. Products in clinical development have the potential to transform standard of care for moderate to severe Campylobacteriosis, Clostridioides difficile infections, Enterotoxigenic Escherichia coli (ETEC) infections and Traveler’s Diarrhea. Immuron markets Travelan® in Australia, Canada and the U.S. In Australia, Travelan® is indicated to reduce the risk of travelers’ diarrhea and to reduce the risk of minor gastro-intestinal disorders. In Canada, Travelan® is indicated to reduce the risk of travelers’ diarrhea. In the U.S, Travelan® is a dietary supplement for digestive tract protection.

About LD Micro

LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Whether it is the Index, comprehensive data, or hosting the most significant events annually, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.

To present or register, please get in touch with Dean@ldmicro.com

To learn more about Freedom US Markets, visit www.freedomusmkts.com

For further information on Immuron Limited:

Steven Lydeamore
CEO
+613 8892 4854
steve@immuron.com
https://www.immuron.com.au/

Immuron Limited American Depositary Shares

NASDAQ:IMRN

IMRN Rankings

IMRN Latest News

IMRN Stock Data

14.12M
188.40M
0.12%
0.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Melbourne

About IMRN

immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (nash) diabetes, colitis, arthritis, inflammatory bowel diseases (ibd), irritable bowel syndrome (ibs), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. these disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile. immuron has one marketed product, which provides proof of concept for its oral immune technology platform, and a pipeline of products at various stages of cl